

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 31/44, 9/10, A61P 1/04</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/50038</b> <b>(43) International Publication Date:</b> 31 August 2000 (31.08.00)
<b>(21) International Application Number:</b> PCT/US00/04170 <b>(22) International Filing Date:</b> 18 February 2000 (18.02.00) <b>(30) Priority Data:</b> 60/121,253 23 February 1999 (23.02.99) US <b>(71) Applicant (for all designated States except US):</b> MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> FREEHAUF, Keith [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). <b>(74) Common Representative:</b> MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> PHARMACEUTICAL COMPOSITION CONTAINING PROTON PUMP INHIBITORS			
<b>(57) Abstract</b>  The present invention is concerned with an oral pharmaceutical formulation containing a proton pump inhibitor (PPI) which is suitable for the treatment of gastric acid related diseases in man and animals. More specifically, the composition is a paste, and is particularly suitable for delivery of a proton pump inhibitor to horses.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**TITLE OF THE INVENTION****PHARMACEUTICAL COMPOSITION CONTAINING PROTON PUMP  
INHIBITORS****5 SUMMARY OF THE INVENTION**

The present invention relates to an improved oral paste formulation of omeprazole.

**BACKGROUND OF THE INVENTION**

10 Omeprazole is a potent inhibitors of gastric acid secretion that acts by inhibiting  $H^+K^+-ATPase$ , the enzyme involved in the final step of hydrogen ion production in the parietal cells, and has been used in the treatment of gastric acid related diseases, such as gastric and duodenal ulcers, in humans. Peptic ulcers are common also in some animals, particularly in horses. Although the etiology of gastro-  
15 duodenal ulcers in horses has not been ascertained, it appears that stress plays an important roles in some cases.

Omeprazole is highly acid labile and hence oral formulations are enteric-coated. Enteric coated formulations are expensive and time consuming to manufacture, and requires elaborate technology and equipment. Another disadvantage  
20 of enteric coated formulation is its moisture sensitivity.

WO94/25070 discloses oral composition containing a proton pump inhibitor in the form of enteric coated dry particles mixed with a dry gelling agent, the mixture may then be made into a paste-like gel prior to administration. The composition therefore requires enteric coating, with the afore-mentioned  
25 disadvantages associated with such formulation. Furthermore, because such a moist gel is not stable during long-term storage at room temperature it cannot be manufactured and sold as a ready-to-use formulation, rather it must be prepared ex tempore at the time of administration, making it inconvenient to use.

US Patent 5,708,017 describes paste formulations of proton-pump  
30 inhibitors comprising a proton-pump inhibitor, a thickening agent, a basifying agent and a hydrophobic oily liquid vehicle.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention provides an improved paste formulation of omeprazole comprising:

- (a) about 1% to about 60% w/w of omeprazole,
- 5 (b) about 0.1% to about 2% w/w of two to four basifying agents,
- (c) about 1% to about 3% w/w of a thickening agent, and
- (d) about 30% to about 95% w/w of a hydrophobic oily liquid vehicle comprising
  - (i) a vegetable oil and
  - 10 (ii) triglycerides of medium chain fatty acids or propylene glycol diesters of medium chain fatty acids.

Omeprazole is disclosed in US Patent 4,255,432. The amount of omeprazole in the present invention is not particularly critical so long as the drug product remains a semi-solid preparation; generally up to about 60% w/w of omeprazole can be tolerated. Preferably the amount of omeprazole is about 50 % w/w or less, and more preferably from about 30 to about 40 % w/w.

Suitable basifying agents are for example pharmaceutically acceptable amine bases such as monoethanolamine, diethanolamine, triethanolamine, or salts of carboxylic acids such as sodium acetate, sodium citrate, potassium sorbate, sodium stearate and the like. Preferably one of the basifying agent is potassium sorbate, and one or two other basifying agents may be selected from an amine base such as monoethanolamine and a carboxylic acid salt such as sodium stearate. The basifying agents are present in an amount sufficient to provide a non-acidic environment for the acid-labile omeprazole; typically, the total amount of basifying agents is from about 20 0.1 to about 2 % w/w, and preferably from about 1 to about 1.5 % w/w.

The thickening agent may be any pharmaceutically acceptable thickener that are insoluble or practically insoluble in water; examples include silicone dioxide, waxes such as castor wax or hydrogenated castor oil, paraffin, cetostearyl alcohol, and the like. The preferred hydrophobic thickener is hydrogenated castor oil. The amount of thickening agent is approximately 0.5% to 30 10% w/w of the final composition; preferably, it is about 1 to 2 % w/w.

The hydrophobic oily liquid vehicle comprises (i) a vegetable oil and (ii) triglycerides of medium chain fatty acids or propylene glycol diesters of medium

chain fatty acids. Examples of vegetable oil include almond oil, cottonseed oil, olive oil, peanut oil, safflower oil, sesame oil, and soybean oil. The preferred vegetable oil is sesame oil. Medium chain fatty acids are those having carbon chain lengths of from eight to twelve; preferably the fatty acids are saturated fatty acids. Preferred

5 triglycerides and propylene glycol diesters are capric/caprylic triglycerides and propylene glycol caprate/caprylate (also referred to as propylene glycol octanoate decanoate). Capric/caprylic triglycerides and propylene glycol caprate/caprylate are commercially available products such as those marketed under the Miglyol®

10 tradename (Huls America, Inc., New Jersey). The more preferred hydrophobic oily liquid vehicle comprises sesame oil and propylene glycol caprate/caprylate (such as Miglyol® 840). The hydrophobic vehicle is present at approximately 30% to 95% w/w, depending on the amount of other excipients in the paste. Preferably the hydrophobic vehicle is present at about 50 to about 80% w/w. In the hydrophobic vehicle the ratio of the vegetable oil to the triglyceride may range from about 1:3 to

15 about 5:1; preferably about 1:1 to about 2:1.

The present composition may include additional ingredients commonly used in the formulation of human and veterinary medicines. For example, flavoring agents such as caramel, carrot, apple, cinnamon and sausage flavors; coloring agents such as iron oxide, titanium dioxide, aluminum lakes; sweeteners such as sugar,

20 sodium saccharin; preservatives such as parabens; antioxidants such as BHT, BHA; dispersants such as calcium stearate, and viscosity regulating agents such as white wax or synthetic waxes such as glyceryl tribehenate, glyceryl trimyristate, hydrogenated coco-glycerides can be added.

The composition of the present invention may be prepared by

25 dispersing omeprazole in powder form in the hydrophobic liquid vehicle containing any other excipients except the thickening agent. The thickening agent is then added to the mixture and mixed to achieve the desired consistency. The composition of the present invention may also be prepared by dispersing the excipients in the hydrophobic oily liquid vehicle, followed by addition of the thickening agent, and if

30 needed additional vegetable oil to achieve the desired consistency; to the resultant mixture is added omeprazole in powder form and the entire mixture is mixed well to disperse the omeprazole. The paste formulation thus obtained may be used to fill

dosing syringes, which may be used directly to administer the active drug to an animal in need of treatment.

5 The omeprazole paste formulations of the present invention have improved properties over previously described omeprazole paste formulations. The present formulations have better chemical and physical stability profiles, and provide higher drug bioavailability.

10 The composition of the present invention are useful in the treatment of peptic ulcer diseases in humans or animals. It can be used to deliver omeprazole orally for systemic activity in animals. The composition can also be used for the delivery of omeprazole in human with difficulty of swallowing solid dosage forms such as enteric coated tablets and capsules. The composition may be administered directly into the mouth of an animal, such as a horse, in need of anti-ulcer therapy; preferably a paste dosing syringe is used to facilitate drug administration. The consistency of this paste is such that it can not easily drip out or be expelled once it is deposited on the dorsal part of the animal's tongue. The paste is practically free of air bubbles which enhances dosing accuracy. Another advantage of this formulation is that individualized doses can be administered.

15 The amount of the composition to be administered may vary according to the particular animal species to be treated, the severity of the disease, the physical condition of the afflicted animal, and other factors. A physician or veterinarian skilled in the art of ulcer treatment may readily determined the proper dosage for the specific host under treatment. In general, a dose range of from about 0.2 mg/kg to about 20 mg/kg may be used.

20 The following example is provided to more fully illustrate the invention, and shall not be construed as limiting the scope of the invention in any manner.

## EXAMPLE 1

<u>Component</u>	<u>Percent w/w</u>
omeprazole base	37.0
potassium sorbate	0.20
sodium stearate	0.10
calcium stearate	1.0
monoethanolamine	0.10
yellow iron oxide	0.20
cinnamon oil	0.30
hydrogenated castor oil	1.25
propylene glycol octanoate decanoate	25.0
sesame oil	qs

Potassium sorbate (0.50 kg), calcium stearate (2.50 kg), sodium stearate (0.25 kg), and yellow iron oxide (0.50 kg) are added to a double cone blender and mixed to disperse powders. The resultant powder is passed through a 60 mesh screen and milled at high speed. This milled powder preblend is collected in a polyethylene bag for use in paste manufacturing.

In a suitably sized vertical screw semi-solid paste mixer are added propylene glycol octanoate decanoate (62.5 kg) and sesame oil (37.5 kg). The temperature of the liquid mixture is adjusted to below approximately 25°C, if necessary, and the mixing screw is turned on. With the lumpbreaker on, the milled powder preblend, monoethanolamine (0.25 kg), and cinnamon oil (0.75 kg) are added to the mixer. Next, hydrogenated castor oil (3.13 kg) is added to the mixer, and mixing is until the product temperature reaches  $50 \pm 5^\circ\text{C}$ . The mixing screw and the lumpbreaker are stopped and the batch in the vessel is held for  $30 \pm 5$  minutes to assure completion of the gelling process.

With cooling water on, the remaining sesame oil (49.6 kg) is added to the mixer. The mixing screw and lumpbreaker are turned on for approximately two minutes to disperse the materials and then stopped. Omeprazole powder (92.5 kg) is added to the mixer in 8 -10 portions; after addition of each portion the mixer is turned on for a period sufficient to wet most of the powder and then turned off for the

addition of the next portion. After all the omeprazole has been added, mixing is continued for an additional 10 minutes to fully disperse the omeprazole; then the lumpbreaker is turned on and mixing continues for an additional 10 minutes to assure complete homogeneity. The resultant paste is used for packaging into syringes.



**WHAT IS CLAIMED IS:**

1. A pharmaceutical formulation for oral administration  
comprising:  
5 (a) about 1% to about 60% w/w of omeprazole,  
(b) about 0.1% to about 2% w/w of two to four basifying agents,  
(c) about 1% to about 3% w/w of a thickening agent, and  
(d) a hydrophobic oily liquid vehicle comprising  
10 (i) a vegetable oil and  
(ii) triglycerides of medium chain fatty acids or propylene  
glycol diesters of medium chain fatty acids.
2. A composition of Claim 1 wherein said thickening agent is  
hydrogenated castor oil.  
15
3. A composition of Claim 1 wherein said hydrophobic liquid  
vehicle comprises propylene glycol caprate/caprylate and a vegetable oil.
4. A composition of Claim 1 wherein said hydrophobic liquid  
20 vehicle comprises sesame oil and triglycerides of medium chain fatty acids or  
propylene glycol diesters of medium chain fatty acids.
5. A composition of Claim 1 wherein said hydrophobic liquid  
vehicle comprises propylene glycol caprate/caprylate and sesame oil.  
25
6. A composition of Claim 1 wherein one of the basifying agents  
is potassium sorbate.
7. A composition of Claim 1 wherein the basifying agents are  
30 potassium sorbate, sodium stearate and monoethanolamine.

8. A composition of Claim 1 wherein the amount of omeprazole is about 30 to about 40 % w/w.
9. A composition of Claim 1 wherein the total amount of  
5 basifying agents is from about 1 to about 1.5% w/w.
10. A composition of Claim 1 wherein the amount of the hydrophobic oily liquid vehicle is about 30% to 90% w/w.
- 10 11. A composition of Claim 1 wherein the amount of the hydrophobic oily liquid vehicle is about 50% to 80% w/w.

# INTERNATIONAL SEARCH REPORT

Int. Appl. No.

PCT/US 00/04170

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/44 A61K9/10 A61P1/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 708 017 A (DAVE KAUSHIK J ET AL) 13 January 1998 (1998-01-13) cited in the application column 1, line 46 - line 65 column 3, line 51 - column 4, line 29 column 5 - column 6; examples 1-5 claims 1-8	1,2,4,6, 8-11
T	"Oral dosage form for new animal drugs; Omeprazole." FEDERAL REGISTER, vol. 64, no. 72, 1999, pages 18572-18573, XP000929106 page 18572, column 3 - page 18573, column 1	1-11

☐ Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

19 July 2000

Date of mailing of the international search report

26/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Muller, S

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/04170

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5708017 A	13-01-1998	AU 703755 B	01-04-1999
		AU 5379796 A	23-10-1996
		BR 9604803 A	09-06-1998
		CA 2217515 A	10-10-1996
		CN 1185107 A	17-06-1998
		CZ 9703135 A	15-04-1998
		EA 87 B	25-06-1998
		EP 0819004 A	21-01-1998
		HU 9801626 A	01-02-1999
		JP 11503160 T	23-03-1999
		NO 974589 A	03-12-1997
		PL 322619 A	02-02-1998
		SK 135097 A	03-06-1998
		WO 9631213 A	10-10-1996
		ZA 9602657 A	09-10-1996